newsfilter
← Latest News
GlobeNewswire·

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of